The North America breast cancer market size was estimated at USD 11.03 billion in 2025 and is projected to be worth around USD 17.13 billion by 2035, is expanding at a CAGR of 4.50% from 2026 to 2035. The Breast Cancer Market in North America is growing due to increasing breast cancer prevalence, advanced healthcare infrastructure, and rising adoption of targeted therapies and AI-based diagnostics.

North America Breast Cancer Market Statical Scope

Precision oncology and AI-based imaging are becoming more and more popular in the North American breast cancer market. Treatment advancements are being supported by the growing demand for immunotherapies and targeted therapies. Healthcare professionals are using cutting-edge screening technologies to concentrate on early detection. Innovation in the area is also being fueled by rising investments in clinical trials and cancer research.

Strong healthcare spending, growing adoption of cutting-edge diagnostic technologies, and the rising incidence of breast cancer are the main drivers of the market. Early disease detection and treatment outcomes are being improved by the growing use of AI-enabled imaging systems and precision oncology solutions. Additionally, growing expenditures for targeted therapy development and clinical research are bolstering regional market expansion.

North America Breast Cancer Market Share, By Therapy Type, 2025 (%)

• Targeted Therapy- The targeted therapy segment dominated the market in 2025, with a share of 29%, owing to the increasing adoption of precision medicine approaches and growing availability of HER2-targeted drugs. It is also driven by the rising preference for therapies with improved treatment outcomes and reduced side effects.
• Hormonal Therapy (Endocrine Therapy)- The hormonal therapy segment held a 24% share and is expected to grow in the coming years, driven by the high prevalence of hormone receptor-positive breast cancer. It is also supported by the widespread use of endocrine-based treatment regimens.

North America Breast Cancer Market Share, By Cancer Type/Molecular Subtype, 2025 (%)

• Hormone Receptor-Positive (HR+)- The hormone receptor-positive segment dominated the market in 2025, with a share of 46%, supported by its high prevalence among breast cancer patients. It is also leading due to a strong demand for endocrine and targeted treatment options.
• HER2-Positive (HER2+)- The HER2-positive segment held a 20% share and is expected to grow in the coming years due to increasing use of HER2-targeted biologics and precision therapies. This cancer type is growing due to gene amplification, acquired mutations, aggressive cell signalling, and increased detection.

North America Breast Cancer Market Share, By Disease Stage, 2025 (%)

• Early-Stage Breast Cancer (Stage 0–II)- The early-stage breast cancer segment dominated the market in 2025, with a share of 56%, owing to rising awareness regarding early diagnosis and widespread mammography screening programs. It is followed by increasing treatment success rates for early-detected cases.
• Locally Advanced Breast Cancer (Stage III)- The locally advanced breast cancer segment held a 24% share and is expected to grow in the coming years, driven by the growing use of combination treatment strategies. They include surgery, chemotherapy, and radiation therapy.

North America Breast Cancer Market Share, By End-Use, 2025 (%)

• Hospitals- The hospitals segment dominated the market in 2025 with a share of 48%, accelerated by high patient volumes and the availability of advanced oncology infrastructure. Hospitals provide access to multidisciplinary cancer treatment services.
• Oncology Clinics/Specialty Clinics- The oncology clinics/specialty clinics segment held a 24% share and is expected to grow in the coming years due to growing preference for specialized outpatient cancer care. They are also expanding due to a shift towards personalized treatment management.

Recent Developments in the Market

• In February 2026, Daiichi Sankyo announced its next move to launch five antibody drug conjugates in 2026 while transitioning from cardiovascular health to antibody drug conjugates. These five launches will represent new indications for Enhertu and Datroway, but one is a novel antibody drug conjugate.

Competitive Landscape

The leading companies in the breast cancer industry are AstraZeneca, Novartis, Pfizer, Roche, Hologic, Eli Lily, and many others. They have offered therapeutic and pharmaceutical solutions for treating HER2-positive metastatic breast cancer, metastatic triple-negative breast cancer (TNBC), etc. The major diagnostics and screening offerings include AI-powered imaging platforms, blood tests, liquid biopsy, and advanced imaging like 3D mammography and MRI. AI is being deeply integrated into radiology, pathology, and drug development to deliver personalized care.

Segments Covered in the Report

By Therapy Type

• Targeted Therapy
• Hormonal Therapy (Endocrine Therapy)
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Combination Therapy

By Cancer Type/Molecular Subtype

• Hormone Receptor-Positive (HR+)
• HER2-Positive (HER2+)
• Triple-Negative Breast Cancer (TNBC)
• Ductal Carcinoma In Situ (DCIS)
• Others

By Disease Stage

• Early-Stage Breast Cancer (Stage 0–II)
• Locally Advanced Breast Cancer (Stage III)
• Metastatic Breast Cancer (Stage IV)

By End-Use

• Hospitals
• Oncology Clinics/Specialty Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Homecare Settings